Rotavirus vaccine: a review.

Abstract

Worldwide, large proportion i.e., 37% of deaths due to diarrhea in young children is attributed to rotavirus. A monovalent P1A[8] G1 vaccine and a pentavalent bovine-human reassortant vaccine human rotavirus vaccine had shown good clinical efficacy without any increase in intussusception among vaccine recipients. WHO recommends that the first dose of rotavirus vaccine should be administered to infants up to age of 6-15 weeks irrespective of the prior history of rotavirus infection and the maximum age for administering the last dose of the vaccine should be 32 weeks. Booster doses are not recommended. The current update reviews the issues related to rotavirus vaccines and their usages like milestones in the development of rotavirus vaccines, concerns regarding their efficacy and cost-effectiveness, immunity after natural infection, potential for changes in virus strains, current recommendations, post marketing surveillance, and future challenges and scope for further research regarding rotavirus vaccines.

• Authors: Goel Manish Kumar, Kumar Arun, Jain Ram Bilas, Jain Ruchi, Khanna Pardeep, Siwach Pradeep
• Journal: The Journal of communicable diseases (J Commun Dis) Vol. 44 Issue 4 Pg. 189-200 (Dec 2012) ISSN: 0019-5138 [Print] India
• PMID: 25145068 (Publication Type: Journal Article, Review)

Chemical References

• Rotavirus Vaccines
• Vaccines, Synthetic

Topics

• Child
• Child, Preschool
• Humans
• Infant
• Intussusception (immunology, prevention & control, virology)
• Rotavirus Infections (immunology, prevention & control)
• Rotavirus Vaccines (administration & dosage)
• Vaccines, Synthetic (administration & dosage)